Latest news
PRESSRELEASE New patent for ICOone
PRESSRELEASE 230126:
The European Patent Office EPO intends to approve Iconovo's patent application for the inhaler platform ICOone® (Communication…
Iconovo i Penserpodden
Penserpodden är en podd om aktier, börs och marknad där några av våra mest framstående förvaltare och analytiker går igenom allt från både…
Press releases
Feb 14, 2019, 08:45
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 04, 2019, 10:58
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Staff change
Jan 25, 2019, 09:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se